Clovis Oncology’s Rubraca (Rucaparib) Granted FDA Priority Review For Advanced Prostate Cancer
Clovis Oncology announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca (rucaparib) and granted…
Read More...
Read More...
